YENOM NOTICIAS
Noticias financieras organizadas para conectar titulares, símbolos, fuente, fecha y sentimiento con tu análisis y operativa.
Si escribes ticker, YENOM prioriza ese instrumento. Si lo dejas vacío puedes explorar el feed general o por tema.
Orthofix Medical Inc. (NASDAQ:OFIX) is one of the Best Small-Cap Growth Stocks to Invest In Now. The stock has declined roughly 22% since its fiscal Q1 2026 earnings. Despite the softness, the Street remains bullish, with analysts' 12-mont…
Orthofix Medical Inc. Q1 2026 Earnings Call Summary - Moby Strategic Execution and Channel Optimization Performance was driven by the successful completion of distributor transitions, with the top 30 partners delivering 27% year-over-year…
ELK CITY, Idaho, July 31, 2023--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI), announced today issuance of a Notice of Allowance from the United States Patent and Trademark Office on its patent application covering a no…
Protection of T Cells from Tumor-Induced Suppression Suggests Potential for Enhancing Efficacy of Checkpoint Inhibitor and CAR-T Therapies Company Plans to Initiate Phase I/II Clinical Trial in Advanced Breast Cancer Patients ELK CITY, Ida…
Company Sets Sights on Dreaded Disease that "Attacks at the Essence of One’s Humanity" ELK CITY, Idaho, July 12, 2023--(BUSINESS WIRE)--Therapeutic Solutions International, Inc. (TSOI), a clinical stage regenerative medicine and immunother…
Clinical Stage Biotech Company Leverages Existing Clinical Data and Phase III Clearance to Accelerate Treatment of Fatal Lung Condition ELK CITY, Idaho, June 26, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced t…
ELK CITY, Idaho, May 25, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced the creation of CTE Biologics, Inc. as a subsidiary company dedicated to commercializing the JadiCell adult stem cell platform for treatme…
ValloVax Cancer Endothelial Stem Cell Technology Repositioned to Overcome Limitations on Multibillion Dollar Cancer Immunotherapy Market ELK CITY, Idaho, May 22, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced t…
Clinical Stage Biotech Company Partners with Premier Compounding Pharmacy to Provide Doses for IRB Cleared Phase I/II Clinical Trial ELK CITY, Idaho, May 15, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) spin-off Res No…
Clinical Stage Company Expands Regenerative Medicine Franchise into 4 billion Dollar Aneurysm Market ELK CITY, Idaho, May 01, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced formation of a new spin-off company,…
Regenerative Medicine Company Leverages Recent Patent Victory and Positive Results to Accelerate Late-Stage Clinical Pulmonary Candidate ELK CITY, Idaho, April 20, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced…
Company Advances towards First Cell Therapy to Prevent Suicidal Associated Mental Illness ELK CITY, Idaho, April 03, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) Spin Off Company Campbell Neurosciences announced new da…
Company Using the Immune System as a "Stethoscope for the Brain" to Identify Individuals with Propensity for Suicide Aims to Revolutionize Practice of Psychiatry ELK CITY, Idaho, March 27, 2023--(BUSINESS WIRE)--Therapeutic Solutions Inter…
Biotech Company Leverages Previous Clinical Trial Blood Based Biomarker Data to Create Point of Care Psychiatric Assessment Tool ELK CITY, Idaho, March 20, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today i…
Company Builds on Previous Observations Correlating Clinical Responses to Stem Cells with Unique B Cell Population ELK CITY, Idaho, March 13, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today new data and fi…
Company Receives Institutional Review Board Approval for 10 Patient Proof of Concept Oncology Trial ELK CITY, Idaho, March 06, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today plans to initiate ten patient…
FDA Phase III Stem Cell Company Offers End Stage Patients Access to FDA Cleared Clinical Trial Stem Cells ELK CITY, Idaho, February 21, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced the launching of the Veltme…
Therapeutic Solutions International Announces Positive Preclinical Results in "Patient Ready" FloraVax Therapy ELK CITY, Idaho, February 14, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today paradigm shiftin…
Breast Cancer Angiogenesis Targeting Immunotherapy Company Aims for a Cure without Toxicity of Conventional Therapies ELK CITY, Idaho, January 30, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today the recrui…
ELK CITY, Idaho, January 23, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today an update on progress made by its subsidiary Campbell Neurosciences, Inc. Campbell was founded on the principle that suicide in…
New Finding May Facilitate Personalized Stem Cell Therapy ELK CITY, Idaho, January 09, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today identification and patent filing of a previously unexpected discovery…
Secondary Finding Demonstrates Tattooing Skin with Tolerogenic Genes AIRE or FoxP3 "Balances" Immune System to Stop Autoimmunity ELK CITY, Idaho, January 04, 2023--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced novel…
Phase III Adult Stem Cell Company Reports Positive Data Through "Right to Try" Accelerated Access Collaboration ELK CITY, Idaho, December 05, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today preliminary res…
Phase III Adult Stem Cell Company Covers Ability of its COVID-19 Nutraceutical to Repair Injured Brain Cells and Stimulate Endogenous Brain Stem Cells ELK CITY, Idaho, November 28, 2022--(BUSINESS WIRE)--Therapeutic Solutions International…
Breathe Biologics Inc., a Pulmonary Regenerative Medicine Subsidiary of TSOI, Discloses Allogeneic Pulmonary Myeloid Suppressor Cell Based Product ELK CITY, Idaho, November 14, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TS…
Phase III Clinical Trial Stem Cell Company Aims to Fast Forward Regenerative Solutions to Dreaded Lung Disease ELK CITY, Idaho, November 09, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today the launching of…
First in Class Antiangiogenic Immunotherapy Offered under Right to Try Law to No Option Patients ELK CITY, Idaho, November 07, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today that its breast cancer focused…
Company to Develop StemVacs-V Anti-Angiogenesis Immunotherapy for Initial Treatment of Breast Cancer ELK CITY, Idaho, October 27, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today formation of a Spin-Off Com…
Phase III Clinical Trial Company Uses Universal Donor Stem Cell to Suppress Brain Inflammation for Multiple Neurological Conditions ELK CITY, Idaho, October 24, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced to…
Commercially Available Nutraceutical Potentially Effective Against COVID-19 Brain Fog ELK CITY, Idaho, October 10, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI) announced today receipt of a "Notice of Allowance" from th…
Clinical Stage Stem Cell Company Leverages Knowledge Gained from Cancer Dendritic Cell Therapy StemVacs to Open New Door for COPD and ARDS Research ELK CITY, Idaho, October 03, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TS…
Company Announces $10,000,000 Common Stock Purchase Agreement with GHS Investments, LLC. ELK CITY, Idaho, September 20, 2022--(BUSINESS WIRE)--Therapeutic Solutions International (TSOI), a clinical stage regenerative medicine and immunothe…
Validation of Efficacy for Second Suicide-Associated Psychiatric Indication Supports Push for Clinical Entry of Novel Brain-Healing Stem Cell Type ELK CITY, Idaho, September 19, 2022--(BUSINESS WIRE)--Therapeutic Solutions International an…
Phase III COVID-19 ARDS Company Continues Quest to Cure COPD Through Developing Clinically Applicable Solutions ELK CITY, Idaho, September 12, 2022--(BUSINESS WIRE)--Therapeutic Solutions International announced today data and patent filin…
Company Continues Accelerated Development of Candidate Pipeline and Patent Portfolio in Respiratory Medicine Space as Phase III Trial Proceeds ELK CITY, Idaho, August 29, 2022--(BUSINESS WIRE)--Therapeutic Solutions International announced…
Company Eyes Targeting 17 Billion Dollar Market Using Universal Donor Adult Stem Cell Therapy ELK CITY, Idaho, August 25, 2022--(BUSINESS WIRE)--Therapeutic Solutions International announced today filing with the Food and Drug Administrati…